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1. Introduction
   Achillis is the largest tendon of the body and has an 
important role in stabilityof body, posture and walking. 
trauma to this tendon is very common especially in Atelets.
The treatment modalities for tendon rupture are diverse.
  These treatments are not complete and have side effects 
and sometime is with pain after the treatment[1]. One of the 
new modalities is PRP injection in the repair site.
  It is shown that PRP can help in healing process of soft and 
hard tissues and has been used in Orthopedics, Dentistry, 
Dermatology, Plastic and Maxillofacial surgeries[2]. Some 
of the studies shown the mitogenic effects of PRP and have 
emphecised on the role of the  growth factors in PRP[3].
  Adhesions is one the problems after tendon repair and 
needs early movement of tendon ,although early movement 
may induce rupture of the tendon[4,5]. To overcome 
these effects some authors suggest using growth factors 
to strenghten the repair site and early start of tendon 
movement. we know that PRP has TGF and VEGF and 
can induce chemotaxis, fibroblast proliferation, collagen 
synthesis, cell proliferation and increase of angiogenesis.
  PRP is an autologus, non expensive and simple tissue 
that has regeneration power, it has no allergic or infectious 
side effects and it is shown that PRP would remain for one 
week in the repair site, so it seemsthat one dose of injection 
would be enough for tendon repair[6-15]. 
2. Materials and methods
  The study was performed on 20 Vaster albinoc male rats, 
weighting 200-250 g and age about 2 months. The rats were 
kept in separate cages with 12 h day and night cycle and 
tempreture of 24-28 degree of centigrade and enough food 
and water. The animals were kept under Helsinky protocol. 
All of the surgeries were done by the same surgeon, Rats 
were anesthetized with Ketamin 15 mg/kg and Xilocaine 5 
mg/kg. Ceftriaxone 60 mg/kg IM were injected into the rats 
before surgery. 2.5 cc of Blood were taken from the rats and 
Objective: To evaluate effects of PRP injection in strengthening of repaired tendon. Methods: 
This study was conducted in animal lab of our hospital on 20 rats. The animals were divided into 
two groups randomly and distal third of left Achillis tendons were cut and then repaired with 
Vicryl 2/0. The first group was control group and  in the second group 0.5 cc of PRP was injected 
into the repair site. After 4 weeks all of the rats were executed and 70% of tendons were sent 
randomly for tensilometry and the force that required to rupture the tendons were measured. In 
next stage the tendons were sent for pathological exam. Results: The force that was needed to 
rupture the tendon were not significantly different in the two groups. Neovascularization were 
more prevalent  in PRP group but not statistically significant. There were two cases of Cartilage 
Metaplasia in PRP group. Conclusion: It seems that using PRP has no effect on  strengthening 
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centrifuged and the PRP was  isolated with pipette .
  Incision were made over  distal  third of Achillis tendon 
and tendons disected and cut in distal third and then 
repaired with Vicryl 4/0 (Figure 1). In first group no other 
treatment was done but in second group 0.5 cc of PRP were 
injected in the repair site then skin closed with nylon 4/0. 
Splint applied over the legs and rats were kept in the cages 
and were free to move. The rats were examined every other 
day by a physician. None of the rats died during the study. 
No infection were seen during the study.
Figure 1. Cuting of the Aschillis tendon.
  After 28 days all of the rats executed with CO2 gas without 
any pain. And the tendons were removed with calcaneous 
bone. Seben tendons in each group were selected randomly 
and  sent for  tensilometry (Figure 2). The force that needed 
to rupture the tendons were measured in newton.
  Five mm by 5 mm of the tendons in the repair site were sent 
for pathologic exam. The pathologist were blinded about the 
two groups. The samples were colored with hematoxilin and 
eosin and studied for the number of fibroblasts, collagenes 
and their orientation and vascularization. Photographies 
were taken from the samples.
  The results were expressed as mean依Standard deviation 
and analyzed with SPSS 16 software. P<0.05 were considered 
significant. For analysing ANOVAtest, Mann-Whitney, 
Wilcoxon, Tukey and Dunnet test were used.
Figure 2. Tendon samples for tensilometry.
 
3. Results
  All of the rats were alive after 28 days. The mean force that 
was needed for tendon rupture were 47 newtons in control 
group and 57 newtons in PRP group (P=0.193). In the control 
group in 2 tendons, rupture happened with force of 40 
newtons. But none of the tendon in PRP group rutured with 
forces less than 40 newtons. The maximum force in control 
group was 70 newtons and in PRP group 82 newtons. In 28% 
of control group rupture happened with forces less than 40 
newtons. And in PRP group, 14% ruptured with forces more 
Table 1
Comparison of forces that need to rupture the tendons after 4 weeks (P=0.193).
Mean Total C7 C6 C5 C4 C3 C2 C1 Control group
47 7 cases 34 43 47 57 43 35 70 Force (Newton)
Mean Total P7 P6 P5 P4 P3 P2 P1 PRP group
57 7 Cases 43 57 63 82 43 45 67 Force (Newton)
Table 2.Comparison of mean of forces that need to rupture the tendons between the two groups (P=0.193).
Difference (%) Control group(Newton) PRP group(Newton)
21% 47 57 Mean
Table 3





- 3+ 3+ 1+ 2+ 1+ 0 C1
- 2+ 2+ 1+ 2+ 2+ 0 C2
- 1+ 2+ 1+ 1+ 1+ 0 C3
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than 80 newtons (Table 1 & 2).
  On average the force that needed for rupture of tendons in 
PRP group were 20 % more than the control group (Figure 3). 
The samples were examined for number of acute and chronic 
phase inflammatory cells, fibroblast, fibrosis, collagene 
fibers orientation,vascularization and metaplasia (Fiugre 4 
& 5). Acute phase infalamatory cells were not found in the 
samples.




Figure 5. Collagen fibrils and orientation.
 
  Fibroblast orientation were not diferent in  both groups. 
Number of fibroblasts were shown in table 3. The difference 
in the two groups were not significant. In PRP group two 
cases of Metaplasia were seen, cartilage Metaplsia was seen 
in two samples (Figure 6 & 7).
Figure 6. Cartilage metaplasia.
 
Figure 7. Cartilage metaplasia after using PRP in tendon.
4. Discussion
  Musculoskeletal injuries are the most common cause of 
severe long-term pain and physical disability, and affect 
hundreds of millions of people around the world. Therapeutic 
approaches to tendon healing do not always result in a 
satisfactory anatomical and functional repair, and healed 
tendon is often characterized by functional impairment and 
high risk of reinjury. Recently, mesenchymal stem cells 
(MSCs) and platelet rich plasma (PRP) have been proposed 
as novel therapeutic treatments to improve the tendon repair 
process. MSCs are multipotent, easy to culture and being 
originated from adult donors do not pose ethical issues. To 
date, autologous MSCs have been investigated mainly in the 
treatment of large bone defects, cardiovascular diseases, 
osteogenesis imperfecta and orthopaedic injuries both in 
human and veterinary medicine[4].
  One of the most popular methods used to biologically 
enhance healing in the fields of hand surgery, orthopaedic 
surgery and sports medicine includes the use of autologous 
blood products, namely, platelet rich plasma (PRP). PRP is 
an autologous concentration of human platelets to supra-
physiologic levels. At baseline levels platelets function as 
a natural reservoir for growth factors including platelet-
derived growth factor (PDGF), epidermal growth factor (EGF, 
transforming growth factor-beta 1 (TGF-毬1), vascular 
endothelial growth factor(VEGF), basic fibroblast growth 
factor (FGF), hepatocyte growth factor (HGF), and insulin-like 
growth factor (IGF-I). Platelet-rich plasma (PRP) is derived 
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from centrifuging whole blood, has a platelet concentration 
higher than that of the whole blood, is a part of  the cellular 
component of plasma that settles after centrifugation[3]. 
and now a days is commonly used in orthopaedic practice 
to augment healing in sports-related injuries of skeletal 
muscle, tendons, and ligaments. Despite its pervasive use, 
the clinical efficacy of PRP therapy and varying mechanisms 
of action have yet to be established. Basic science research 
has revealed that PRP exerts is effects through many 
downstream events secondary to release of growth factors 
and other bioactive factors from its alpha granules. These 
effects may vary depending on the location of injury and the 
concentration of important growth factors involved in various 
soft tissue healing responses. Current findings in PRP basic 
science research, which have shed light on its proposed 
mechanisms of action, have opened doors for future areas 
of PRP research. We know that specific growth factors may 
play a crucial role in the healing process. There is abundant 
enthusiasm in the application of concentrated platelets, 
which release a supra-maximal quantity of these growth 
factors to stimulate recovery in  injuries. 
  There is increasing interest in the sports medicine and 
athletic  community about providing endogenous growth 
factors directly to the injury site using autologous blood 
products such as PRP, to potentially facilitate healing and 
earlier and faster return to sport after musculoskeletal 
injury[3].
  Platelet rich plasma (PRP) , the autologous plasma 
fraction with a platelet-rich cellular component, Due to its 
availability and low cost, has become an increasingly popular 
clinical tool as an alternative source of growth factors for 
various applications, for example tendon regeneration 
but with limited success in clinical trials[5]. Platelet-
rich plasma (PRP) therapy aims to improve the process of 
tissue repair through local delivery of autologous bioactive 
agents to influence critical physiological mechanisms 
such as inflammation angiogenesis, or extracellular matrix 
synthesis. These biological properties have prompted the 
therapeutic administration of PRP in reconstructive and 
sports medicine. Given its biocompatibility and healing 
properties, percutaneous injections of PRP are also  used 
in athletes to treat tendon and muscle injuries[30] and 
also for the treatment of ligament, cartilage injuries and 
early osteoarthritis[38], lateral epicondylitis, ligament and 
muscle strains, and tears of the rotator cuff anterior cruciate 
ligament, and Achilles tendon[16]. Platelet-rich plasma  can 
be applied at the site of injury either during surgery or 
through an injection performed in the physician’s office. 
And many investigators are exploring the ways in which this 
therapy can be used in the clinical setting. However, there is 
little published clinical evidence that proves its efficacy in 
treating the multitude of injuries/disorders that are thought 
to benefit from PRP[16]. the potential risks involved with 
PRP are fortunately very low. However, benefits remain 
unproven to date[3]. PRP use in tendon and ligament injuries 
has several potential advantages, including faster recovery 
and, possibly, a reduction in recurrence, with no adverse 
reactions described[17]. Some results indicate that PRP exerts 
anti-inflammatory effects on injured tendons through HGF. 
This study provides basic scientific evidence to support 
the use of PRP to  treat injured tendons because PRP can 
reduce inflammation and thereby reduce the associated pain 
caused by high levels of PGE2[18] and reduction in pain may 
facitilate earlymovement of tendon and limb.
  In 2010. Zhang et al reported that PRP treatment of injured 
tendons is “safe” as it promotes TSC differentiation into 
tenocytes rather than nontenocytes, which would adverse 
effects on the structure and function of healing tendons by 
formation of nontendinous tissues. Moreover, they suggest 
that PRP treatment can enhance tenocytes to proliferate 
quickly and produce abundant  collagen to repair injured 
tendons[19].
  PRP secretes many growth factors, including transforming 
growth factor beta1 (TGF-beta1), platelet derived growth 
factor, vascular endothelial growth factor, insulin-
like growth factor 1, and so on, which can induce cell 
proliferation, chemotaxis, and collagen synthesis for wound 
healing. it is shown that PRP can facilitate rabbit’s tendons 
healing and significantly improve the healing quality[20]. 
PRP is also used in conjunction with other product such 
as: TCA[21], MSCs [22], ASCs[23],  fibrin matrix[24], TSC tendon 
stem cells[25], Leukocyte- and platelet-rich plasma[26], The 
“Cascade” membrane  a thin layer of autologous fibrine 
that is very rich in platelets and is obtained by high speed 
centrifugation of a small quantity of PRP[27].
  The repair process of tendon injuries,  is slow and the 
quality of the repair tissue is often inferior to the original 
tendon tissue, which frequently leads to re-injury. 
The relatively poor vascularization of tendons is one of 
the reasons. PRP, rich in growth factors, enhance the 
vascularization.The vascular endothelial growth factor, a 
powerful stimulator of angiogenesis, is abundantly present 
in PRP suggesting that enhancement of neovascularization 
might be one of the  mechanisms. Bosch et al in 2011 shown 
that PRP induced significantly more neovascularization than 
the placebo treatment until at least 23 weeks after treatment, 
as detected by both Doppler ultrasonography and Factor 
VIII staining long-lasting effect[28] and it has Lyras et al 
also stated that The poor vascularity of tendons is a major 
factor in their limited healing capacity. Their study shown 
significantly more angiogenesis in the PRP group  during the 
first two weeks of the healing process, i.e inflammatory and 
proliferative phase . 
  The number of the newly formed vessels in the PRP 
group were significantly reduced at 4 weeks compared to 
the controls (P<0.0001) meaning that the healing process 
was shortened. And concluded that PRP may accelerate 
the healing process and promote scar tissue of better 
histological quality[29]. Histologically it is seen that healing 
process in the tendons of PRP group is faster. In the first 2 
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weeks of healing, IGF-1 was found intracellularly in various 
type cells, whereas in the last 2 weeks of healing IGF-1 was 
detected mainly in tenocytes. Both cytoplasmic and nuclear 
expressions were present, whereas the larger amounts of 
immunoexpression were localized in both epitenon and 
endotenon. And it was concluded that  PRP may improve 
tendon defect healing by overexpression of IGF-1[30]. 
  In early phases of tendon healing processes, circulation-
derived cells temporarily exist in the wounded area to initiate 
the healing process and decrease in number with time. In a 
study Kajikawa et al said that  a delay of time-dependent 
decrease in circulation-derived cells could improve the 
healing of tendons. They injected PRP into the wounded 
area of the patellar tendon, and compared the effects on 
activation of circulation-derived cells and enhancement 
of tendon healing and concluded that locally injected PRP 
is useful as an activator of circulation-derived cells for 
enhancement of the initial tendon healing process[31]. The 
repair of subcutaneous tendon ruptures can be stimulated 
by a single application of one of several growth factors 
[e.g. platelet-derived growth factor (PDGF), transforming 
growth factor (TGF)-beta, insulin-like growth factor 
(IGF)-1, vascular endothelial growth factor (VEGF), bone 
morphogenetic proteins (BMPs) like growth differentiation 
factor (GDF)-5, -6, -7]. The response to these measures is 
dependent on the mechanical microenvironment. So far, 
almost all research has been limited to rodent models, 
mostly using the rat Achilles tendon[32].
  PRP increases metabolic activity and seems to advance 
maturation of repair tissue over nontreated experimentally 
induced tendon lesions, which suggests that PRP might be 
beneficial in the treatment of clinical tendon injuries[33]. 
Also Mechanical stimulation improves the repair of ruptured 
tendons. Injection of PRP can also improve repair in several 
animal models. In a rat Achilles tendon transection model, 
one postoperative injection resulted in increased strength 
after 4 weeks. Considering the short half-lives of factors 
released by platelets, this very late effect calls for an 
explanation that Platelets influence only the early phases of 
regeneration, but this allows mechanical stimulation to start 
driving neo-tendon development at an earlier time point[34].
Many commercial preparation systems for PRP therapy are 
available, but the optimal preparation remains unknown. 
Increasing numbers of clinical studies evaluating PRP have 
been reported and have provided both positive and negative 
evidence for its effectiveness. Well-designed, controlled 
studies are still lacking, but PRP may have a benefit for 
patients with tendinopathy that is refractory to other non-
surgical treatments. Its use in tendon repair is currently not 
supported
  Randomized, controlled studies with documentation of 
platelet, white blood cell, and growth factor concentration 
in the PRP preparation are necessary for future comparative 
research[35]. However, whatever is the machanism of 
action of PRP, the result has to be a stenghthen and strong 
tendon that would not rupture again. There are reports 
that an injection of PRP in sectioned rat Achilles tendon 
influences the early phase of tendon healing and results in 
an ultimately stronger mechanical resistance[34,36,37]. And in 
contrast other studies showed that a single injection of PRP 
appears not useful for Achilles rat tendon tear[38,39]
  In this study we examined the result of using PRP and 
measured the force that are needed to re-rupture the newly 
repaired tendon. Our results showed that the tensile strenght 
of tendons in PRP group are more but not significantly 
different. Also we examined the samples histologically to 
find any sign of remained or delayed healing process in the 
tendons. The results revealed that the healing process are 
complete after 4 weeks in both groups and   there  is not any 
delay in its process. The collagen fibers and their orientation 
are the same. The orientation of collagen fibers in the PRP 
group was better organized but not different significantly.
  And interestingly the vascularization in the two groups 
were not different significantly. Therefore our result does 
not support using PRP as an adjuvant in treatment of tendon 
ruptures. PRP has not strenghtened the tendon repair site 
and did not improve the mechanical properties of repaired 
tendon. More over accidental finding of two cases of 
metaplasia  is a warning alert sign. Existance of Metaplasia 
in treatment site is a new finding (complication?)and varant 
further comprehensive studies in this kind of therapy .
  PRP does not improve tendon rupture healing. It seems that 
all aspects of using PRP are not completely underestood and 
further studies are still necessary to find its role in healing 
procees. Cartilage metaplasia, as far as we know, hasnot 
been reported yet in PRP treatment  and may have some 
adverse effects on the results of tendon repair.
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